抗瓜氨酸化、氨甲酰化及乙酰化肽自身抗体对新发类风湿关节炎影像学进展的影响:观察性队列研究
基于苏格兰早期类风湿关节炎(SERA)起始队列中362例新发RA患者,基线检测抗修饰蛋白抗体(AMPA)并随访1年手足X线Sharp-van der Heijde评分。单阳性与AMPA阴性患者间无差异。提示预测RA影像学进展需评估针对多种翻译后修饰蛋白的自身抗体。
要点
- 三阳性(ACPA+AAPA+抗氨甲酰化肽抗体)患者1年影像学进展高于ACPA单阳性患者。
- ACPA单阳性与AMPA阴性患者间影像学进展无显著差异。
- 预测RA影像学进展可能需要检测针对多种翻译后修饰蛋白的自身抗体。
核心结论
- 该研究提示,最佳预测RA患者未来影像学进展速度需要评估针对多种翻译后修饰蛋白或肽的自身抗体。
研究设计与样本
- 观察性队列研究,样本与数据来自苏格兰早期类风湿关节炎(SERA)起始队列和生物样本库,2011年3月1日至2015年4月30日招募。
- 纳入362例新发RA患者并测定AMPA谱,其中233例同时具备抗体数据和足够质量的影像学资料。
- 基线用ELISA检测血浆AMPA,基线和1年拍摄手足配对X线并用Sharp-van der Heijde(SvH)法评分。
- 采用估计边际均值变化计算基线至1年影像学进展差异,协变量包括影像学变量基线值、类风湿因子、性别、招募时年龄、症状持续时间及DAS28-CRP。
主要发现
- 362例RA患者按翻译后修饰反应性分为四组:ACPA单阳性73例(20%)、ACPA与AAPA双阳性45例(12%)、ACPA/AAPA/抗氨甲酰化肽抗体三阳性151例(42%)、AMPA阴性74例(20%)。
- 19例(5%)属于次要自身抗体组。
临床怎么用
- 对早期RA患者可考虑检测ACPA、AAPA和抗氨甲酰化肽抗体等AMPA谱,以识别影像学进展风险较高的三阳性患者。
局限性
- 仅233例患者同时具备抗体数据和足够质量的影像学资料用于进展分析。
- 原文未报告研究局限性的具体描述。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A range of anti-modified protein antibodies (AMPAs) are associated with rheumatoid arthritis. We aimed to assess the relationship between AMPA profiles and radiographic progression in patients with new-onset rheumatoid arthritis. METHODS: In this cohort study, we obtained samples and data from the Scottish Early Rheumatoid Arthritis (SERA) inception cohort and biobank, which recruited patients with new-onset rheumatoid arthritis or undifferentiated arthritis who had at least one swollen joint from 20 hospitals across Scotland. AMPAs in plasma samples were measured by ELISAs at baseline. Paired radiographs of the hands and feet were taken at baseline and at 1 year and were scored with the Sharp-van der Heijde (SvH) method. We calculated differences in radiographic progression using estimated marginal mean changes between baseline and 1 year, with the baseline values of radiographic variables, rheumatoid factor, sex, age at recruitment, symptom duration, and Disease Activity Score 28 with C-reactive protein included as covariates. FINDINGS: Between March 1, 2011, and April, 30, 2015, 1073 patients were recruited to the SERA study. 362 patients with rheumatoid arthritis were included in our study and had their AMPA profiles determined. Patients were grouped into four main autoantibody profiles by reactivities to post-translational modifications: single positivity for anti-citrullinated peptide antibodies (ACPAs; 73 [20%]); double positivity for ACPAs and anti-acetylated peptide antibodies (AAPAs; 45 [12%]); triple positivity for ACPAs, AAPAs, and anti-carbamylated peptide antibodies (151 [42%]); and AMPA negativity (74 [20%]). 19 (5%) patients were in one of the minor autoantibody groups. Of the 233 patients with both antibody data and radiographs of sufficient quality, triple-positive patients had more radiographic progression between baseline and 12 months (estimated mean change in total SvH score 1·8, 95% CI 0·9-2·6, SE 0·4) than did single-positive patients (0·5, 0·1-1·0, 0·2; estimated mean difference in the total change in SvH score 1·2, 95% CI 0·1-2·4, SE 0·5). There was no difference in radiographic progression between single positive patients and AMPA negative patients (estimated mean change in total SvH score 0·7, 95% CI 0·1-1·4, SE 0·3; estimated mean difference in the total change in SvH score -0·2, 95% CI -1·1 to 0·7, SE 0·4). INTERPRETATION: This study suggests that the optimal prediction of future rates of radiographic progression in patients with rheumatoid arthritis will require an assessment of autoantibodies against multiple post-translationally modified proteins or peptides. FUNDING: The EU FP7 HEALTH programme, the Scottish Translational Medicine Research Collaboration, and the Chief Scientist Office Scotland.
引用
- Nijjar JS, Morton FR, Bang H, et al. The impact of autoantibodies against citrullinated, carbamylated, and acetylated peptides on radiographic progression in patients with new-onset rheumatoid arthritis: an observational cohort study. Lancet Rheumatol. 2021. PMID: 34604794. doi:10.1016/S2665-9913(20)30381-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。